Daryl Jacobs
Cardiovascular Disease · Chesterfield, MONPI 1770686958
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 324 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,829 and has fallen 83.3% since, to $305 in 2025.
Across 324 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$1K
- Johnson & Johnson$746
- AstraZeneca$589
- Medtronic$510
- Sanofi-aventis U.S. LLC$316
- Amgen$311
- plus $3K from 30 others
What the payments were for
- Food & beverage$6,510100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 49 | $1,028 |
| Johnson & Johnson | 38 | $746 |
| AstraZeneca | 31 | $589 |
| Medtronic | 5 | $510 |
| Sanofi-aventis U.S. LLC | 10 | $316 |
| Amgen | 19 | $311 |
| Novartis | 25 | $299 |
| United Therapeutics Corporation | 15 | $284 |
| Regeneron Healthcare Solutions, Inc. | 10 | $232 |
| Actelion Pharmaceuticals US, Inc. | 15 | $213 |
| Mylan Specialty L.p. | 7 | $196 |
| Boston Scientific | 5 | $195 |
| Pfizer | 12 | $181 |
| Grifols USA, LLC | 9 | $170 |
| Amarin Pharma, Inc. | 13 | $163 |
| Electromed, Inc. | 12 | $161 |
| Sanofi | 7 | $153 |
| Abiomed | 1 | $144 |
| Kowa Pharmaceuticals America, Inc. | 9 | $112 |
| Merck | 5 | $83 |
| Philips North America LLC | 3 | $62 |
| GSK | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Edwards Lifesciences | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Bayer | 2 | $29 |
| Sunovion Pharmaceuticals Inc. | 2 | $23 |
| Bardy Diagnostics, Inc. | 2 | $20 |
| Gilead | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Verona Pharma, Inc. | 1 | $16 |
| Viatris Specialty LLC | 1 | $16 |
| Abbott | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,515 in reported general payments places this provider in the 70th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Chesterfield
- James EllisonChesterfield$267K
- Glenn DavisonChesterfield$118K
- Edward HurleyChesterfield$19K
- Keith MankowitzChesterfield$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James FairlambColumbia$342K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.